- Home
- HASI vs BLTE Comparison
HASI vs BLTE Comparison
Compare HASI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- BLTE
- Stock Information
- Founded
- HASI 1981
- BLTE 2018
- Country
- HASI United States
- BLTE United States
- Employees
- HASI N/A
- BLTE N/A
- Industry
- HASI Real Estate Investment Trusts
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- HASI Real Estate
- BLTE Health Care
- Exchange
- HASI Nasdaq
- BLTE Nasdaq
- Market Cap
- HASI 3.4B
- BLTE 4.1B
- IPO Year
- HASI 2013
- BLTE 2022
- Fundamental
- Price
- HASI $33.57
- BLTE $123.83
- Analyst Decision
- HASI Strong Buy
- BLTE Strong Buy
- Analyst Count
- HASI 8
- BLTE 6
- Target Price
- HASI $39.50
- BLTE $113.80
- AVG Volume (30 Days)
- HASI 1.4M
- BLTE 146.4K
- Earning Date
- HASI 11-06-2025
- BLTE 11-10-2025
- Dividend Yield
- HASI 5.01%
- BLTE N/A
- EPS Growth
- HASI 27.54
- BLTE N/A
- EPS
- HASI 2.32
- BLTE N/A
- Revenue
- HASI $99,644,000.00
- BLTE N/A
- Revenue This Year
- HASI $184.74
- BLTE N/A
- Revenue Next Year
- HASI N/A
- BLTE N/A
- P/E Ratio
- HASI $14.49
- BLTE N/A
- Revenue Growth
- HASI N/A
- BLTE N/A
- 52 Week Low
- HASI $21.98
- BLTE $49.00
- 52 Week High
- HASI $34.28
- BLTE $144.99
- Technical
- Relative Strength Index (RSI)
- HASI 62.93
- BLTE 63.64
- Support Level
- HASI $31.98
- BLTE $105.88
- Resistance Level
- HASI $33.68
- BLTE $144.99
- Average True Range (ATR)
- HASI 1.19
- BLTE 10.83
- MACD
- HASI 0.04
- BLTE 0.58
- Stochastic Oscillator
- HASI 87.10
- BLTE 60.37
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.